Menopausal Genitourinary Syndrome in Older Women: A Comprehensive Clinical Review

Abstract

Menopausal genitourinary syndrome (GSM) represents a constellation of symptoms and signs resulting from estrogen deficiency affecting the vulvovaginal and lower urinary tract in postmenopausal women. This review synthesizes current scientific evidence on the epidemiology, pathophysiology, risk factors, clinical presentation, diagnostic approaches, and management strategies of GSM, with a focus on recent advances and guideline-based recommendations. The article aims to equip healthcare professionals with updated, practical knowledge to improve the detection and management of GSM, ultimately enhancing quality of life in older women.

Introduction

Menopausal genitourinary syndrome, previously referred to as vulvovaginal atrophy or atrophic vaginitis, encompasses a spectrum of chronic symptoms caused by the decline in estrogen and other sex steroids during menopause. GSM impacts the external genitalia, vagina, urethra, and bladder, resulting in sexual, urinary, and psychosocial morbidity. Despite its high prevalence, GSM is frequently underdiagnosed and undertreated, largely due to stigma and lack of patient-provider communication. This comprehensive review aims to provide clinicians with a detailed understanding of GSM, including its epidemiology, underlying mechanisms, risk factors, clinical manifestations, diagnostic strategies, and evidence-based management, while highlighting recent therapeutic advances and guideline recommendations.

Epidemiology / Disease Burden

GSM is highly prevalent among postmenopausal women, with estimates suggesting that up to 50-70% experience symptoms, though actual numbers may be higher due to underreporting. Symptom severity tends to increase with advancing age and years since menopause. The impact on quality of life is profound, with many women experiencing discomfort, sexual dysfunction, relationship stress, and reduced self-esteem. GSM-related urinary symptoms, such as dysuria and recurrent urinary tract infections, further contribute to morbidity. The growing aging population worldwide underscores the increasing clinical and public health importance of GSM.

Pathophysiology

The pathogenesis of GSM is primarily driven by hypoestrogenism following menopause. Estrogen deficiency leads to thinning of the vaginal epithelium, decreased collagen and elastin in the vulvovaginal tissues, reduced vascularity, and diminished glandular secretions. These changes disrupt the vaginal microbiome, resulting in an elevated pH and a decrease in lactobacilli, which further predisposes to infection and inflammation. Urogenital tissues, including the urethra and bladder trigone, similarly rely on estrogen for structural integrity and function, explaining the overlap of urinary symptoms in GSM. The chronicity of these changes distinguishes GSM from transient, self-limited conditions.

Risk Factors

In addition to natural menopause, specific risk factors enhance susceptibility to GSM. These include premature ovarian insufficiency, bilateral oophorectomy, pelvic radiation or chemotherapy, smoking (which impairs tissue vascularity), low body mass index, and lack of sexual activity. Use of anti-estrogenic medications, such as aromatase inhibitors or selective estrogen receptor modulators, is also associated with higher risk. A family history of early menopause and certain genetic factors may contribute. Understanding individual risk factors aids in targeted screening and counseling.

Clinical Features

GSM encompasses a wide range of symptoms affecting the genital, sexual, and urinary domains. Common complaints include vaginal dryness, burning, itching, irritation, dyspareunia, and postcoital bleeding. Urinary manifestations include dysuria, urgency, frequency, nocturia, stress incontinence, and recurrent urinary tract infections. On examination, findings may include pale, thin, inelastic vulvovaginal mucosa, loss of rugae, decreased vaginal depth, labial fusion, and urethral prominence. These symptoms are chronic and progressive, rarely resolving without intervention, and can be mistaken for infectious or dermatologic conditions.

Diagnosis

The diagnosis of GSM is primarily clinical, based on symptomatology and physical examination. A thorough history should elicit genitourinary symptoms, impact on quality of life, sexual activity, and relevant risk factors. Pelvic examination reveals characteristic atrophic changes. Laboratory testing is not routinely required but can be useful to exclude infection or assess vaginal pH (>5 is suggestive of GSM) and presence of parabasal cells on cytology. Differential diagnoses include lichen sclerosus, lichen planus, vulvar dermatoses, and infections. Shared decision-making and sensitive communication are key to effective diagnosis.

Treatment & Management

Management strategies for GSM are tailored to symptom severity, patient preference, and contraindications. First-line therapy for mild symptoms is non-hormonal, including regular use of vaginal moisturizers and lubricants. Behavioral measures, such as regular sexual activity and pelvic floor exercises, may provide adjunctive benefit. For moderate to severe symptoms, local vaginal estrogen therapy (creams, tablets, rings) is highly effective, restoring epithelial health and alleviating symptoms with minimal systemic absorption. Alternatives include intravaginal dehydroepiandrosterone (DHEA) and selective estrogen receptor modulators (ospemifene). Systemic estrogen therapy may be considered if vasomotor symptoms coexist, but risks and benefits must be carefully weighed. Ongoing patient education and follow-up are essential.

Recent Advances / Emerging Therapies

Recent years have witnessed the development of novel non-estrogenic therapies for GSM, addressing safety concerns in women with hormone-sensitive malignancies or contraindications to estrogen. Intravaginal DHEA has shown efficacy in improving both vaginal and urinary symptoms. Selective estrogen receptor modulators, such as ospemifene, offer oral therapy for vulvovaginal symptoms without stimulating endometrial or breast tissue. Energy-based therapies (e.g., fractional CO2 laser, radiofrequency devices) are being investigated for refractory cases, though more robust long-term safety data are needed before widespread adoption. Research into the vaginal microbiome and regenerative therapies may further expand future treatment options.

Guideline Recommendations

Professional guidelines from organizations such as the North American Menopause Society (NAMS), International Society for the Study of Women's Sexual Health (ISSWSH), and American College of Obstetricians and Gynecologists (ACOG) emphasize patient-centered care, shared decision-making, and individualized therapy. Non-hormonal options are recommended as first-line for mild symptoms, with local estrogen as the preferred option for moderate to severe cases unless contraindicated. Systemic therapy is reserved for women with coexistent vasomotor symptoms. Routine monitoring, periodic re-evaluation, and attention to patient concerns about safety, especially in women with a history of breast cancer, are vital components of care.

Conclusion

Menopausal genitourinary syndrome is a prevalent, chronic condition in older women that significantly impairs quality of life. Early recognition, empathetic communication, and evidence-based management are critical to improving patient outcomes. Advances in both hormonal and non-hormonal therapies have broadened the therapeutic armamentarium, allowing individualized care. Ongoing research and multidisciplinary collaboration will further enhance understanding and management of GSM, ensuring better health and well-being for postmenopausal women.